Medidata Rave Selected by Wyeth Pharmaceuticals for Enterprise-Wide EDC Deployment

Medidata Solutions, a global provider of electronic clinical data
capture (EDC), management and reporting solutions, today announced
that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has
selected Medidata Rave(R) as its enterprise-wide EDC solution. This
strategic partnership with Medidata will further enhance Wyeth's
clinical operations and build upon successful EDC programs already in
place.

"The deployment of EDC technology has been an extremely important
initiative at Wyeth - in the past 11 months, we have increased the
rate of EDC usage in trials to more than 90 percent," said Ira
Spector, Vice President of Clinical Development Operations at Wyeth
Research. "The implementation of Medidata Rave is critical to our
ability to further increase and maximize our EDC usage while
continuing to improve the overall productivity of our R&D
organization."

One of the top 10 largest pharmaceutical companies in the world,
Wyeth plans to conduct several hundred global studies using Medidata
Rave during a seven-year term, with the first trial beginning in the
first quarter of 2008.

In order to select its next-generation EDC solution that would
support the increasing volume of its R&D pipeline, Wyeth conducted an
evaluation of vendors in 2006. Wyeth narrowed its selection to two
leading companies and chose Medidata Solutions for Rave's breadth of
functionality as well as the company's depth of experience in the
marketplace and overall corporate culture. Wyeth anticipates Medidata
Rave will bring higher productivity and increased efficiencies and
also offer a range of ease-of-use capabilities to the investigators
that are of such critical importance to the clinical trial process.

"We are extremely pleased that Wyeth has selected Medidata Rave as
its enterprise-wide EDC solution and are committed to collaborating
with the company to advance its clinical processes," said Tarek
Sherif, CEO at Medidata Solutions. "Wyeth's strategic decision to move
to Medidata Rave as its EDC standard is further proof that our
industry-leading technology is the system of choice for life sciences
companies of all sizes. Over the past two years, we have seen the
industry increasingly move to global, enterprise-wide implementations
of Medidata Rave, reflecting the versatility and scalability of our
product and services."

About Medidata Solutions Worldwide

Medidata Solutions helps the world's leading pharmaceutical,
biotechnology, medical device and research organizations maximize the
value of their clinical research investments. Innovative process
design, technology and services streamline clinical trials by
providing early visibility to reliable clinical data - the lifeblood
of every research organization. Working with companies and
institutions both large and small, Medidata Solutions helps clinical
researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80
countries. Medidata Solutions brings significant value to its broad
client base with deep clinical experience and expertise in more than
20 therapeutic areas, projects in Phase I, II, III, IV, registries and
surveillance, and studies with thousands of investigators and
tens-of-thousands of subjects. For more information, please visit
www.mdsol.com.